Article
Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.
EBioMedicine - 1 Jun 2020
de Wit Maurice, Gao Ya, Mercieca Darlene, de Heer Iris, Valkenburg Bart, van Royen Martin E, Aerts Joachim, Sillevis Smitt Peter, French Pim
Abstract excerpt
BACKGROUND: Clinical responses to EGFR tyrosine kinase inhibitors (TKIs) are restricted to tumors harboring specific activating mutations and even then, not all tyrosine kinase inhibitors provide clinical benefit. All TKIs however, effectively inhibit EGFR phosphorylation regardless of the mutation present. METHODS: High-throughput, high-content imaging analysis, western blot, Reversed phase protein arrays, mass...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.